Spots Global Cancer Trial Database for cediranib maleate

Every month we try and update this database with for cediranib maleate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer	NCT01116648	Fallopian Tube ... Ovarian Endomet... Ovarian High Gr... Ovarian Serous ... Ovarian Serous ... Primary Periton... Triple-Negative...	Biopsy Biospecimen Col... Cediranib Malea... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02446600	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima...	Biospecimen Col... Carboplatin Cediranib Malea... Computed Tomogr... Echocardiograph... Gemcitabine Gemcitabine Hyd... Laboratory Biom... Magnetic Resona... Multigated Acqu... Olaparib Paclitaxel Pegylated Lipos... Pharmacological... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer	NCT00278343	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	cediranib malea... laboratory biom...	19 Years -	National Cancer Institute (NCI)
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma	NCT00662506	Adult Giant Cel... Adult Glioblast... Adult Gliosarco...	Cediranib Malea... Diffusion Tenso... Diffusion Weigh... Dynamic Contras... Fludeoxyglucose... Intensity-Modul... Laboratory Biom... Perfusion Magne... Positron Emissi... Temozolomide	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	NCT00475150	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult...	cediranib malea... laboratory biom...	18 Years -	National Cancer Institute (NCI)
AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer	NCT00410904	Recurrent Non-s...	cediranib malea... pemetrexed diso...	18 Years -	National Cancer Institute (NCI)
Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer	NCT00795340	Lung Cancer	carboplatin cediranib malea... paclitaxel placebo	18 Years -	Canadian Cancer Trials Group
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers	NCT01229111	Adult Primary C... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Localized Unres... Periampullary A... Recurrent Adult... Recurrent Extra... Recurrent Gallb... Unresectable Ex... Unresectable Ga...	cediranib malea... oxaliplatin leucovorin calc... fluorouracil	18 Years -	National Cancer Institute (NCI)
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer	NCT02345265	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Carcino... Ovarian High Gr... Ovarian High Gr... Primary Periton... Primary Periton... Primary Periton...	Biopsy Biospecimen Col... Cediranib Malea... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib Questionnaire A...	18 Years -	National Cancer Institute (NCI)
Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery	NCT01229930	Cervical Cancer	carboplatin cediranib malea... paclitaxel laboratory biom... pharmacological... quality-of-life...	18 Years -	National Cancer Institute (NCI)
Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer	NCT00795340	Lung Cancer	carboplatin cediranib malea... paclitaxel placebo	18 Years -	Canadian Cancer Trials Group
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	NCT00475150	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult...	cediranib malea... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy	NCT00527124	Adenocarcinoma ... Stage IV Prosta...	cediranib malea... docetaxel prednisone laboratory biom...	18 Years -	National Cancer Institute (NCI)
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer	NCT00275028	Fallopian Tube ... Primary Periton... Recurrent Ovari... Stage I Ovarian... Stage II Ovaria...	cediranib malea...	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer	NCT00937482	Male Breast Can... Stage IV Breast... Stage IV Melano... Stage IV Non-sm... Stage IV Renal ... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... Tumors Metastat...	cediranib malea... whole-brain rad...	18 Years -	National Cancer Institute (NCI)
AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer	NCT00410904	Recurrent Non-s...	cediranib malea... pemetrexed diso...	18 Years -	National Cancer Institute (NCI)
Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer	NCT00326599	Lung Cancer	carboplatin cediranib malea... gemcitabine hyd...	18 Years -	Alliance for Clinical Trials in Oncology
Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver Cancer	NCT00238394	Adult Primary H... Advanced Adult ... Localized Unres...	cediranib malea... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer	NCT01116648	Fallopian Tube ... Ovarian Endomet... Ovarian High Gr... Ovarian Serous ... Ovarian Serous ... Primary Periton... Triple-Negative...	Biopsy Biospecimen Col... Cediranib Malea... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer	NCT00427973	Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult...	cediranib malea... laboratory biom... computed tomogr... dynamic contras... pharmacological...	18 Years -	National Cancer Institute (NCI)
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors	NCT02498613	Advanced Malign... Metastatic Lung... Metastatic Lung... Metastatic Panc... Metastatic Trip... Pancreatic Duct... Stage III Breas... Stage III Lung ... Stage III Lung ... Stage III Pancr... Stage IIIA Brea... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Brea... Stage IIIB Lung... Stage IIIB Lung... Stage IIIC Brea... Stage IV Breast... Stage IV Lung N... Stage IV Lung S... Stage IV Pancre... Triple-Negative... Unresectable Lu... Unresectable Pa... Unresectable Pa... Unresectable Tr...	18F-Fluoromison... Cediranib Malea... Laboratory Biom... Olaparib Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer	NCT01208051	Refractory Diff... Refractory Thyr... Refractory Thyr... Refractory Thyr... Unresectable Th...	Cediranib Cediranib Malea... Laboratory Biom... Lenalidomide	18 Years -	National Cancer Institute (NCI)
AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer	NCT00303862	Clear Cell Rena... Recurrent Renal... Stage IV Renal ...	cediranib malea... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel	NCT01260688	Hormone Refract... Recurrent Prost...	cediranib malea... dasatinib	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery	NCT00227760	Recurrent Renal... Stage IV Renal ...	Cediranib Malea... Dynamic Contras... Laboratory Biom... Pharmacological...	19 Years -	National Cancer Institute (NCI)
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	NCT00475150	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult...	cediranib malea... laboratory biom...	18 Years -	National Cancer Institute (NCI)
AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer	NCT00303862	Clear Cell Rena... Recurrent Renal... Stage IV Renal ...	cediranib malea... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer	NCT02502266	Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Primary Periton... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Cediranib Cediranib Malea... Computed Tomogr... Magnetic Resona... Olaparib Paclitaxel Pegylated Lipos... Questionnaire A... Topotecan Topotecan Hydro...	18 Years -	National Cancer Institute (NCI)
S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery	NCT00243074	Advanced Malign... Epithelial Meso... Recurrent Malig... Sarcomatous Mes...	cediranib malea... laboratory biom...	18 Years -	National Cancer Institute (NCI)
AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer	NCT00343408	Colorectal Canc... Lung Cancer	cediranib malea... cisplatin fluorouracil gemcitabine hyd... leucovorin calc... oxaliplatin	18 Years - 120 Years	Canadian Cancer Trials Group
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer	NCT01208051	Refractory Diff... Refractory Thyr... Refractory Thyr... Refractory Thyr... Unresectable Th...	Cediranib Cediranib Malea... Laboratory Biom... Lenalidomide	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery	NCT00309946	Advanced Malign... Epithelial Meso... Localized Malig... Recurrent Malig... Sarcomatous Mes...	cediranib malea...	18 Years -	National Cancer Institute (NCI)
AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer	NCT00310089	Breast Cancer	filgrastim pegfilgrastim cediranib malea... cyclophosphamid... docetaxel doxorubicin hyd... laboratory biom... conventional su... neoadjuvant the...	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma	NCT00979862	Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult...	Cediranib Malea... Cilengitide Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors	NCT01131234	Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Brain Ste... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Mixed Gli... Adult Solid Neo... Male Breast Car... Recurrent Adult... Recurrent Breas... Recurrent Colon... Recurrent Melan... Recurrent Non-S... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Recurrent Renal... Stage III Pancr... Stage III Renal... Stage IIIA Colo... Stage IIIA Non-... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Rect... Stage IIIA Skin... Stage IIIB Brea... Stage IIIB Colo... Stage IIIB Non-... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Rect... Stage IIIB Skin... Stage IIIC Brea... Stage IIIC Colo... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Rect... Stage IIIC Skin... Stage IV Breast... Stage IV Non-Sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Renal ... Stage IV Skin M... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta...	Gamma-Secretase... Cediranib Malea... Pharmacological... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma	NCT01062425	Adult Glioblast... Adult Gliosarco...	3-Dimensional C... Cediranib Malea... Intensity-Modul... Laboratory Biom... Placebo Adminis... Temozolomide	18 Years -	National Cancer Institute (NCI)
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine	NCT00326872	Neurofibromatos... Plexiform Neuro... Spinal Cord Neu...	Cediranib Malea...	18 Years -	National Cancer Institute (NCI)
Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer	NCT00795340	Lung Cancer	carboplatin cediranib malea... paclitaxel placebo	18 Years -	Canadian Cancer Trials Group
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma	NCT02974621	Recurrent Gliob...	Bevacizumab Cediranib Cediranib Malea... Olaparib	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone	NCT03660826	Endometrial Ade... Endometrial Mix... Endometrial Ser... Endometrial Und... Endometrioid Ad... Stage IV Uterin...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Capivasertib Cediranib Cediranib Malea... Computed Tomogr... Durvalumab Echocardiograph... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors	NCT02498613	Advanced Malign... Metastatic Lung... Metastatic Lung... Metastatic Panc... Metastatic Trip... Pancreatic Duct... Stage III Breas... Stage III Lung ... Stage III Lung ... Stage III Pancr... Stage IIIA Brea... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Brea... Stage IIIB Lung... Stage IIIB Lung... Stage IIIC Brea... Stage IV Breast... Stage IV Lung N... Stage IV Lung S... Stage IV Pancre... Triple-Negative... Unresectable Lu... Unresectable Pa... Unresectable Pa... Unresectable Tr...	18F-Fluoromison... Cediranib Malea... Laboratory Biom... Olaparib Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer	NCT02899728	Extensive Stage...	Carboplatin Cediranib Cediranib Malea... Cisplatin Etoposide Olaparib	18 Years -	National Cancer Institute (NCI)
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)	NCT00244881	Male Breast Can... Recurrent Breas... Stage IV Breast...	cediranib malea... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer	NCT00278343	Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	cediranib malea... laboratory biom...	19 Years -	National Cancer Institute (NCI)
Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab	NCT00588900	Colorectal Canc...	cediranib malea... irinotecan hydr...	18 Years -	Alliance for Clinical Trials in Oncology
AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer	NCT00310089	Breast Cancer	filgrastim pegfilgrastim cediranib malea... cyclophosphamid... docetaxel doxorubicin hyd... laboratory biom... conventional su... neoadjuvant the...	18 Years -	National Cancer Institute (NCI)
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma	NCT01062425	Adult Glioblast... Adult Gliosarco...	3-Dimensional C... Cediranib Malea... Intensity-Modul... Laboratory Biom... Placebo Adminis... Temozolomide	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	NCT01132820	Endometrial Ade... Endometrial Ade... Endometrial Cle... Endometrial Ser... Recurrent Uteri...	Cediranib Malea... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery	NCT00309946	Advanced Malign... Epithelial Meso... Localized Malig... Recurrent Malig... Sarcomatous Mes...	cediranib malea...	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone	NCT03660826	Endometrial Ade... Endometrial Mix... Endometrial Ser... Endometrial Und... Endometrioid Ad... Stage IV Uterin...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Capivasertib Cediranib Cediranib Malea... Computed Tomogr... Durvalumab Echocardiograph... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer	NCT00427973	Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult...	cediranib malea... laboratory biom... computed tomogr... dynamic contras... pharmacological...	18 Years -	National Cancer Institute (NCI)
AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme	NCT00305656	Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult...	cediranib malea...	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer	NCT00458978	Recurrent Hypop... Recurrent Laryn... Recurrent Laryn... Recurrent Lip a... Recurrent Metas... Recurrent Nasal... Recurrent Nasop... Recurrent Oral ... Recurrent Oroph... Recurrent Saliv... Salivary Gland ... Squamous Cell C... Stage IV Hypoph... Stage IV Laryng... Stage IV Laryng... Stage IV Lip an... Stage IV Major ... Stage IV Nasal ... Stage IV Nasoph... Stage IV Oral C... Stage IV Oropha... Tongue Carcinom... Untreated Metas...	Cediranib Malea... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents	NCT04739800	Fallopian Tube ... Ovarian Seromuc... Platinum-Refrac... Platinum-Refrac... Platinum-Refrac... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Low G... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Plati... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima... Refractory Fall... Refractory Fall... Refractory Fall... Refractory Fall... Refractory Fall... Refractory Fall... Refractory Low ... Refractory Ovar... Refractory Ovar... Refractory Ovar... Refractory Ovar... Refractory Ovar... Refractory Ovar... Refractory Ovar... Refractory Ovar... Refractory Prim... Refractory Prim... Refractory Prim... Refractory Prim... Refractory Prim... Refractory Prim...	Biospecimen Col... Cediranib Malea... Computed Tomogr... Computed Tomogr... Durvalumab Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib Paclitaxel Pegylated Lipos... Topotecan Hydro...	18 Years -	National Cancer Institute (NCI)
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma	NCT01064648	Epithelioid Mes... Pleural Maligna... Recurrent Malig... Sarcomatoid Mes...	Cediranib Malea... Cisplatin Laboratory Biom... Pemetrexed Diso... Placebo Adminis...	18 Years -	National Cancer Institute (NCI)
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma	NCT00662506	Adult Giant Cel... Adult Glioblast... Adult Gliosarco...	Cediranib Malea... Diffusion Tenso... Diffusion Weigh... Dynamic Contras... Fludeoxyglucose... Intensity-Modul... Laboratory Biom... Perfusion Magne... Positron Emissi... Temozolomide	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies	NCT01364051	Metastatic Mela... Refractory Mali... Stage IV Cutane... Unresectable Ma...	Cediranib Cediranib Malea... Laboratory Biom... Pharmacological... Selumetinib Selumetinib Sul...	18 Years -	National Cancer Institute (NCI)
Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma	NCT00979862	Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult...	Cediranib Malea... Cilengitide Laboratory Biom...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: